OPNT

Opiant Pharmaceuticals Announces Positive Top-line Results of Confirmatory Pharmacokinetic (PK) Study for OPNT003, Nasal Nalmefene, a Novel Investigational Treatment for Opioid Overdose

Opiant Pharmaceuticals to Present at the 2021 Jefferies Virtual Healthcare Conference

Opiant Pharmaceuticals to Hold Virtual 2021 Annual Shareholder Meeting on Tuesday, June 15, 2021 at 9:00am PDT

Opiant Pharmaceuticals, Inc. (OPNT) CEO Roger Crystal on Q1 2021 Results - Earnings Call Transcript

Opiant Pharmaceuticals: Q1 Earnings Insights

Opiant Pharmaceuticals Announces First Quarter 2021 Financial Results and Corporate Update

Opiant Pharmaceuticals Announces First Subjects Dosed in Study Comparing OPNT003, Nasal Nalmefene, With Nasal Naloxone